Consonance-Hfw Acq Corp (SRZN) Stock Price, Quote & News

Company Profile

Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 489 9000

Website: www.surrozen.com

Address:

171 Oyster Point Boulevard, Suite 400, South San Francisco, United States

BuyoutBobby Sep. 6 at 10:08 AM

$SRZN So Regeneron hired Nida from Sanofi to build up its ophthalmology pipeline. Then they are also hiring these: Associate Medical Director, Clinical Development, Ophthalmology Senior Medical Director, Clinical Development, Ophthalmology Associate Director, Clinical Scientist, Ophthalmology Director, Program Operations Leader - Ophthalmology/Renal It seems like Regeneron builds a whole new team around Nida to work on the assets that they will acquire.

0 · Reply

BuyoutBobby Sep. 5 at 8:05 AM

$SRZN Merck attacked our patents in 4 places. The most important attack in the US failed July 21 when the PGR was denied. For Merck our patents are definitely important or they wouldn't do that. The question is did the July 21 decision change Merck's strategy from attacking to acquiring Surrozen? Possibly but that will not be easy with Regeneron, Roche and BI who also care about Surrozen and the WNT patent estate.

0 · Reply

BuyoutBobby Sep. 1 at 11:43 AM

$SRZN Regeneron hired a very interesting person today with Hatice Nida Sen. She was formerly at Sanofi building their ophthalmology franchise and beforehand she was at J&J working together with Daniel Chao who is our VP. At Sanofi she was also responsible for external innovation. She was the board observer at 2 companies: Character Biosciences: GA/AMD precision-medicine pipeline Memento Medicines: Tie2 agonist + VEGF inhibitor bispecific antibody for nAMD/DME She left these boards to be able to join Regeneron. So Regeneron just hired the perfect person to fill up their empty ophthalmology pipeline and she has experience with VEGF combination drugs.

1 · Reply

BuyoutBobby Aug. 31 at 2:49 PM

$SRZN Boehringer Ingelheim is already doing their own WNT drug research: https://pmc.ncbi.nlm.nih.gov/articles/PMC13355717/?utm_source=chatgpt.com

0 · Reply

BuyoutBobby Aug. 28 at 9:06 PM

$SRZN seems like Surrozen will go to this conference in Vienna. https://euretina.org/eis-2026/contributors/

0 · Reply

BuyoutBobby Aug. 28 at 1:23 PM

$SRZN i found this interesting term of the Surrozen/BI license from 2022: "For five years after the effective date of the CLA, Surrozen is prohibited from preclinically and clinically developing or commercializing Fzd4 bi-specific antibodies for any diseases of the eye, and BI is prohibited from clinically developing or commercializing Licensed Products for any purpose other than diseases of the eye. " Maybe that is the reason of the license dispute with BI. But there is also another interesting information. BI licensed SZN-413 not only in ophthalmology it got a license in all fields but can only start clinical development of those non ophthalmology indications after 5 years. That means BI could already get preclinical candidates with SZN-413 against stroke, Alzheimer's and other neurologic diseases during the 5 years but only start clinical development afterwards.

1 · Reply

BuyoutBobby Aug. 28 at 10:43 AM

$SRZN i think it makes more and more sense that the February 2026 patent publications of Surrozen triggered multiple companies to start or intensify the due diligence of Surrozen. 3 patents of Surrozen were published on February 26 after Merck started the patent attack in the US. The patents actually name other IL-6 drugs like tocilizumab, satralizumab and vamikibart(Roche) and sarilumab(Regeneron). But i think what is more important is the general potential of combining anti inflammatory drugs with potentially regenerative WNT activation and the overlap that our involved companies have. Regeneron/Sanofi could combine Sarilumab or Dupixent with WNT activation. Roche could combine their IL-6 drugs with ours. They are working on RG6981 which is TSLP + IL-33 inhibition against COPD which could work with WNT activation. Merck acquired Verona Pharma for approximately $10 billion in 2025 for ensifentrine which is a PDE3/PDE4 inhibitor which could work in combination with WNT activation.

1 · Reply

Scorpole Aug. 27 at 4:21 PM

$SRZN It looks like so much, that someone has been told to keep SP around $24 at any cost.

1 · Reply

BuyoutBobby Aug. 26 at 5:19 PM

$SRZN Merck was interested to acquire Revolution Medicines for $28-32 billion in January. Now with FDA approval the company is much more expensive. At the same time Merck and Moderna got good trial results for a Keytruda combination. Merck will probably not go back to Revolution and offer $50-60 billion now. It is possible that Merck will look for smaller bolt on acquisitions like Surrozen for example. They are obviously interested and have to choose between fighting our patents for years, fighting our patents in the hands of Regeneron or acquiring Surrozen.

0 · Reply

BuyoutBobby Aug. 25 at 3:43 PM

$SRZN with Merck not asking for a rehearing it seems like potentially acquiring Surrozen was more important. If they got full VDR access in July then the announcement of the buyout could follow soon. I guess we will get it in the next 4 weeks.

0 · Reply

Surrozen to Present at Upcoming Healthcare Investor Conferences

2026-08-20T10:05:24.000Z - 18 days ago

Surrozen initiated with an Outperform at William Blair

Aug 6, 2026, 4:05 PM EDT - 4 weeks ago

Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 6, 2026, 7:00 AM EDT - 4 weeks ago

Surrozen Quarterly report: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 4 weeks ago

Surrozen Earnings release: Q2 2026

Jul 22, 2026, 1:00 PM EDT - 6 weeks ago

Surrozen Transcript: H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

Jul 15, 2026, 4:05 PM EDT - 7 weeks ago

Surrozen to Present at Upcoming Healthcare Investor Conference

May 19, 2026, 11:30 AM EDT - 3 months ago

Surrozen Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 13, 2026, 1:00 PM EDT - 3 months ago

Surrozen Transcript: AGM 2026

2026-05-07T11:30:10.000Z - 4 months ago

Surrozen price target raised to $44 from $36 at H.C. Wainwright

2026-05-07T01:00:24.000Z - 4 months ago

Surrozen reports Q1 EPS ($11.65) vs. ($7.43) last year

May 6, 2026, 4:05 PM EDT - 4 months ago

Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update

May 6, 2026, 4:00 PM EDT - 4 months ago

Surrozen Earnings release: Q1 2026

May 6, 2026, 4:00 PM EDT - 4 months ago

Surrozen Quarterly report: Q1 2026

May 5, 2026, 6:00 PM EDT - 4 months ago

Surrozen Slides: Corporate presentation

2026-04-29T22:03:27.000Z - 4 months ago

Surrozen management to meet with Cantor

Apr 28, 2026, 4:05 PM EDT - 4 months ago

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2026-04-21T09:41:40.000Z - 4 months ago

Surrozen initiated with a Buy at TD Cowen

Apr 1, 2026, 8:00 AM EDT - 5 months ago

Surrozen Proxy statement: Proxy filing

Apr 1, 2026, 8:00 AM EDT - 5 months ago

Surrozen Proxy statement: Proxy filing

2026-03-24T10:15:11.000Z - 5 months ago

Surrozen price target raised to $36 from $32 at H.C. Wainwright

2026-03-23T21:30:13.000Z - 5 months ago

Surrozen files $200M mixed securities shelf

Mar 23, 2026, 4:05 PM EDT - 5 months ago

Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 23, 2026, 4:00 PM EDT - 5 months ago

Surrozen Annual report: Q4 2025

Mar 23, 2026, 4:00 PM EDT - 5 months ago

Surrozen Earnings release: Q4 2025

Mar 23, 2026, 8:00 AM EDT - 5 months ago

Surrozen Registration statement: Registration filing

Mar 23, 2026, 7:00 AM EDT - 5 months ago

Surrozen Slides: Corporate presentation

Mar 4, 2026, 1:10 PM EST - 6 months ago

Surrozen Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-19T11:15:51.000Z - 6 months ago

Surrozen initiated with an Overweight at Cantor Fitzgerald

Feb 12, 2026, 1:30 PM EST - 6 months ago

Surrozen Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Dec 3, 2025, 3:25 PM EST - 9 months ago

Surrozen Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 9:30 AM EST - 9 months ago

Surrozen Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-11-13T11:15:34.000Z - 9 months ago

Surrozen initiated with an Outperform at LifeSci Capital

Nov 12, 2025, 9:30 AM EST - 9 months ago

Surrozen Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-07T21:20:19.000Z - 10 months ago

Surrozen names Andrew Maleki as CFO

Nov 7, 2025, 4:05 PM EST - 10 months ago

Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 7, 2025, 4:00 PM EST - 10 months ago

Surrozen Earnings release: Q3 2025

Nov 7, 2025, 4:00 PM EST - 10 months ago

Surrozen Quarterly report: Q3 2025

Nov 6, 2025, 6:00 PM EST - 10 months ago

Surrozen Slides: Corporate Presentation

Sep 10, 2025, 11:30 AM EDT - 12 months ago

Surrozen Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 4:15 PM EDT - 1 year ago

Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 4, 2025, 8:00 AM EDT - 1 year ago

Surrozen Transcript: Cantor Global Healthcare Conference 2025

Aug 13, 2025, 7:00 AM EDT - 1 year ago

Surrozen Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 8, 2025, 4:05 PM EDT - 1 year ago

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 8, 2025, 7:00 AM EDT - 1 year ago

Surrozen Quarterly report: Q2 2025

Aug 8, 2025, 7:00 AM EDT - 1 year ago

Surrozen Earnings release: Q2 2025

2025-05-20T20:35:11.000Z - 1 year ago

Surrozen files $150M mixed securities shelf

May 20, 2025, 8:00 AM EDT - 1 year ago

Surrozen Registration statement: Registration Filing

2025-05-14T12:37:05.000Z - 1 year ago

Surrozen granted patent from USPTO directed to antibody-based molecules

May 14, 2025, 8:30 AM EDT - 1 year ago

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

May 9, 2025, 4:05 PM EDT - 1 year ago

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

May 9, 2025, 12:30 PM EDT - 1 year ago

Surrozen Earnings release: Q1 2025

May 9, 2025, 12:30 PM EDT - 1 year ago

Surrozen Quarterly report: Q1 2025

2025-04-23T20:29:24.000Z - 1 year ago

Surrozen files to sell 5.21M shares of common stock for holders

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Surrozen Registration statement: Registration Filing

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Surrozen Proxy statement: Proxy Filing

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Surrozen Proxy statement: Proxy Filing

2025-03-31T20:40:11.000Z - 1 year ago

Surrozen reports FY24 EPS ($21.67) vs. ($21.33) last year

Mar 31, 2025, 4:05 PM EDT - 1 year ago

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 31, 2025, 3:00 PM EDT - 1 year ago

Surrozen Annual report: Q4 2024

Mar 31, 2025, 3:00 PM EDT - 1 year ago

Surrozen Earnings release: Q4 2024

2025-03-25T19:46:20.000Z - 1 year ago

Surrozen to discontinue development of SZN-043 in alcohol associated hepatitis

Mar 24, 2025, 9:00 AM EDT - 1 year ago

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

2025-01-30T11:05:29.000Z - 1 year ago

Surrozen initiated with a Buy at H.C. Wainwright

2025-01-03T12:15:21.000Z - 1 year ago

Guggenheim upgrades Surrozen to Buy after ‘encouraging’ SZN-043 data

Nov 19, 2024, 2:25 PM EST - 1 year ago

Surrozen Transcript: Stifel 2024 Healthcare Conference

Nov 13, 2024, 3:00 PM EST - 1 year ago

Surrozen Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 6, 2024, 9:00 AM EST - 1 year ago

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

Nov 5, 2024, 6:00 PM EST - 1 year ago

Surrozen Earnings release: Q3 2024

Nov 5, 2024, 6:00 PM EST - 1 year ago

Surrozen Quarterly report: Q3 2024

Nov 4, 2024, 8:30 AM EST - 1 year ago

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Sep 24, 2024, 8:30 AM EDT - 1 year ago

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Aug 12, 2024, 4:05 PM EDT - 2 years ago

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Aug 12, 2024, 7:00 AM EDT - 2 years ago

Surrozen Quarterly report: Q2 2024

Aug 12, 2024, 7:00 AM EDT - 2 years ago

Surrozen Earnings release: Q2 2024

Jun 12, 2024, 8:30 AM EDT - 2 years ago

Surrozen Publishes Study in ‘eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Jun 10, 2024, 8:30 AM EDT - 2 years ago

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

Jun 4, 2024, 8:30 AM EDT - 2 years ago

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

May 9, 2024, 8:30 AM EDT - 2 years ago

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

May 8, 2024, 4:05 PM EDT - 2 years ago

Surrozen Provides First Quarter 2024 Financial Results and Business Update

May 8, 2024, 7:00 AM EDT - 2 years ago

Surrozen Quarterly report: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

Surrozen Earnings release: Q1 2024

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Surrozen Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Surrozen Proxy statement: Proxy Filing

Apr 18, 2024, 8:00 AM EDT - 2 years ago

Surrozen Registration statement: Registration Filing

Apr 10, 2024, 4:00 PM EDT - 2 years ago

Surrozen Earnings release: Q4 2023

Apr 10, 2024, 4:00 PM EDT - 2 years ago

Surrozen Annual report: Q4 2023

Apr 3, 2024, 8:40 AM EDT - 2 years ago

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

Apr 1, 2024, 8:30 AM EDT - 2 years ago

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

Apr 1, 2024, 8:30 AM EDT - 2 years ago

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

Jan 18, 2024, 8:30 AM EST - 2 years ago

Surrozen Provides Corporate Update on Clinical Programs

Nov 8, 2023, 4:05 PM EST - 2 years ago

Surrozen Provides Third Quarter 2023 Financial Results

Nov 8, 2023, 7:00 AM EST - 2 years ago

Surrozen Quarterly report: Q3 2023

Nov 8, 2023, 7:00 AM EST - 2 years ago

Surrozen Earnings release: Q3 2023

Oct 24, 2023, 8:00 AM EDT - 2 years ago

Surrozen Proxy statement: Proxy Filing

Oct 24, 2023, 8:00 AM EDT - 2 years ago

Surrozen Proxy statement: Proxy Filing

Oct 13, 2023, 8:00 AM EDT - 2 years ago

Surrozen Proxy statement: Proxy Filing

Aug 9, 2023, 4:05 PM EDT - 3 years ago

Surrozen Provides Second Quarter 2023 Financial Results

Aug 9, 2023, 7:00 AM EDT - 3 years ago

Surrozen Quarterly report: Q2 2023

Aug 9, 2023, 7:00 AM EDT - 3 years ago

Surrozen Earnings release: Q2 2023

Jun 5, 2023, 8:30 AM EDT - 3 years ago

Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke

May 10, 2023, 4:05 PM EDT - 3 years ago

Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates

May 10, 2023, 4:00 PM EDT - 3 years ago

Surrozen Quarterly report: Q1 2023

May 10, 2023, 4:00 PM EDT - 3 years ago

Surrozen Earnings release: Q1 2023

Apr 6, 2023, 8:00 AM EDT - 3 years ago

Surrozen Proxy statement: Proxy Filing

Apr 6, 2023, 8:00 AM EDT - 3 years ago

Surrozen Proxy statement: Proxy Filing

Apr 5, 2023, 8:30 AM EDT - 3 years ago

Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

Mar 22, 2023, 4:30 PM EDT - 3 years ago

Surrozen Earnings Call Transcript: Q4 2022

Mar 22, 2023, 4:30 PM EDT - 3 years ago

Surrozen Annual report: Q4 2022

Mar 22, 2023, 4:30 PM EDT - 3 years ago

Surrozen Earnings release: Q4 2022

Mar 22, 2023, 4:30 PM EDT - 3 years ago

Surrozen Slides: Q4 2022

Mar 22, 2023, 4:01 PM EDT - 3 years ago

Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

Mar 20, 2023, 4:30 PM EDT - 3 years ago

Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

Jan 4, 2023, 4:41 PM EST - 3 years ago

Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference

Dec 9, 2022, 7:00 AM EST - 3 years ago

Surrozen Registration statement: Registration Filing

Nov 14, 2022, 4:30 PM EST - 3 years ago

Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Oct 10, 2022, 8:00 AM EDT - 3 years ago

Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week

Oct 6, 2022, 8:00 AM EDT - 3 years ago

Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases

Sep 26, 2022, 8:00 AM EDT - 3 years ago

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy

Aug 11, 2022, 8:00 AM EDT - 4 years ago

Surrozen Reports Second Quarter 2022 Financial Results

Jun 13, 2022, 8:00 AM EDT - 4 years ago

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

May 24, 2022, 8:00 AM EDT - 4 years ago

Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

May 18, 2022, 8:00 AM EDT - 4 years ago

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

May 16, 2022, 8:00 AM EDT - 4 years ago

Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Dise

May 11, 2022, 8:00 AM EDT - 4 years ago

Surrozen Reports First Quarter 2022 Financial Results

May 5, 2022, 8:00 AM EDT - 4 years ago

Surrozen to Present at the BofA Securities 2022 Healthcare Conference

May 2, 2022, 8:00 AM EDT - 4 years ago

Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Apr 28, 2022, 8:00 AM EDT - 4 years ago

Surrozen Proxy statement: Proxy Filing

Apr 28, 2022, 8:00 AM EDT - 4 years ago

Surrozen Proxy statement: Proxy Filing

Mar 29, 2022, 8:00 AM EDT - 4 years ago

Surrozen Registration statement: Registration Filing

Mar 28, 2022, 8:00 AM EDT - 4 years ago

Surrozen Annual report: Q4 2021

Mar 24, 2022, 8:00 AM EDT - 4 years ago

Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results

Jan 10, 2022, 8:00 AM EST - 4 years ago

Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline

Jan 5, 2022, 8:00 AM EST - 4 years ago

Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Nov 15, 2021, 4:00 PM EST - 4 years ago

Surrozen Reports Third Quarter 2021 Financial Results

BuyoutBobby Sep. 6 at 10:08 AM

0 · Reply

BuyoutBobby Sep. 5 at 8:05 AM

0 · Reply

BuyoutBobby Sep. 1 at 11:43 AM

1 · Reply

BuyoutBobby Aug. 31 at 2:49 PM

$SRZN Boehringer Ingelheim is already doing their own WNT drug research: https://pmc.ncbi.nlm.nih.gov/articles/PMC13355717/?utm_source=chatgpt.com

0 · Reply

BuyoutBobby Aug. 28 at 9:06 PM

$SRZN seems like Surrozen will go to this conference in Vienna. https://euretina.org/eis-2026/contributors/

0 · Reply

BuyoutBobby Aug. 28 at 1:23 PM

1 · Reply

BuyoutBobby Aug. 28 at 10:43 AM

1 · Reply

Scorpole Aug. 27 at 4:21 PM

$SRZN It looks like so much, that someone has been told to keep SP around $24 at any cost.

1 · Reply

BuyoutBobby Aug. 26 at 5:19 PM

0 · Reply

BuyoutBobby Aug. 25 at 3:43 PM

0 · Reply

BuyoutBobby Aug. 22 at 7:48 PM

$SRZN so the overlap between Merck and Surrozen is actually bigger than i expected. They both started working on WNT + VEGF combination molecules. Surrozen has the earlier priority date for their patent and is more advanced in the development. If Merck wants freedom to operate then they have to acquire Surrozen. If they don't do it then somebody else will do it and then Merck has to fight the patent battle against Regeneron for example. And Regeneron can't really let another big pharma company acquire aflibercept combination molecules so they have a reason to pay more than any other bidder. Interesting times here especially in the very near future.

0 · Reply

BuyoutBobby Aug. 22 at 11:02 AM

$SRZN kinda interesting what you find looking at the patents. Merck and Surrozen both applied for WNT + VEGF combination molecule patents.

0 · Reply

BuyoutBobby Aug. 22 at 8:08 AM

$SRZN just recently Merck/Eyebio published a WNT review and the message is very interesting. It was prepared in 2025 so while Merck was working on the patent attack they also prepared a very favourable scientific message about Surrozen's WNT and WNT/aflibercept drugs. So Merck funded the patent attack but also scientific reasons to watch and potentially acquire Surrozen. In connection with the termination of the US patent attack this is very interesting.

0 · Reply

BuyoutBobby Aug. 21 at 6:25 PM

$SRZN Surrozen added some consultants in 2026. I found Roger Goldberg, Mark Barakat, David Eichenbaum and Sobha Sivaprasad which is a nice group of people.

0 · Reply

BuyoutBobby Aug. 21 at 1:45 PM

$SRZN right now it looks like Merck didn't try to get a rehearing for the PGR. The deadline expired yesterday August 20 and today still nothing. No more PGR means our patent stays valid and Merck has to find another way of solving this problem. Regeneron, Roche and Boehringer Ingelheim also know now that Merck could be more serious about acquiring Surrozen. Very good for our negotiation leverage.

0 · Reply

BuyoutBobby Aug. 20 at 12:03 PM

$SRZN Merck changed the name of Restoret to remigromig which is interesting to officially start using the new name since August 2026. Also the phase 3 trial win from yesterday for the cancer vaccine in cooperation with Moderna was a big win for Merck which could also influence how aggressive they will bid in a buyout for Surrozen.

0 · Reply

Quantumup Aug. 20 at 10:33 AM

William Blair🏁 $SRZN and said -- We are initiating coverage of Surrozen with an Outperform rating and fair value estimate of $51 per share. $MRK $OCUL EYPT REGN RHHBY FDMT KOD OCS William Blair added—Surrozen is a biotechnology company developing multispecific antibodies that leverage Wnt agonism-and specifically FZD4 agonism -for the treatment of serious retinal diseases. While Wnt agonism is a relatively new mechanism in vascular retinopathies, Phase I/II data with Merck/EyeBio's MK-3000 (remigromig; formerly Restoret) demonstrated clinical proof-of-concept, and we expect the first Phase III readout in second half 2026. Surrozen has developed a more potent FZD4 agonist, SZN-413, which it licensed to Boehringer Ingelheim in 2022, and is now focused on a portfolio of multispecific antibodies leveraging that same FZD4 agonist backbone but with additional functionality.

0 · Reply

BuyoutBobby Aug. 20 at 7:10 AM

$SRZN Surrozen management was in New York again. That is the second time multiple people of Surrozen fly to New York to meet with analysts which they could easily meet per Zoom so that is interesting. May 19, 2026 — H.C. Wainwright BioConnect, New York at least Parker + Maleki August 2026 — Guggenheim NDR, New York Parker + Maleki + Williams + Chao Management meetings can be part of buyout negotiations and New York is the perfect place for them.

0 · Reply

BuyoutBobby Aug. 18 at 8:33 PM

$SRZN i already wrote about this drug when it disappeared from Regeneron's pipeline but now it is officially gone. https://www.fiercebiotech.com/biotech/regeneron-ends-eye-disease-trial-anti-cd3-antibody-following-safety-review

0 · Reply

BuyoutBobby Aug. 18 at 1:00 PM

$SRZN that is an interesting timeline. Can it all be coincidence that this is happening after TCG prepares the company for a buyout since Q4 2025? TCGX selling 325000 shares in a negotiated block trade is also very interesting here. Who could have been the buyer of those shares? Maybe RA Capital that would make sense and could fit perfectly because they would still be at less than 10% ownership afterwards. It would fit their past behavior of "syndicating" with each other.

0 · Reply

BuyoutBobby Aug. 17 at 10:28 AM

$SRZN TCGX made an IPO for a SPAC(Special Purpose Acquisition Company). They could be preparing this to acquire something. It could even be connected to Surrozen. They could acquire non core assets that are not highly valued in a buyout. Surrozen has a lot of preclinical assets that could have value but not much value to a big pharma company that is mainly interested in the ophthalmology drugs. Surrozen also still has SZN-043. So theoretically they could use this SPAC to acquire some assets of Surrozen. https://www.sec.gov/Archives/edgar/data/2137965/000119312526336098/d85347d424b4.htm

0 · Reply

BuyoutBobby Aug. 16 at 5:48 PM

$SRZN that is the drug that Surrozen worked on with TCG/TCGFB. The question is who got the asset after TCGFB was dissolved in December 2025. If Surrozen then that's huge if somebody else then it still shows what Surrozen can do in just 1 year and with very little money burn. https://www.biorxiv.org/content/10.64898/2026.08.11.744117v1

0 · Reply

Market Cap	264.24M
Revenue (ttm)	3.48M
Net Income (ttm)	-242.03M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,954.89%
Debt to Equity Ratio	0.00

Volume	150,200
Avg Vol	233,170
Day's Range	N/A - N/A
Shares Out	11.61M
Stochastic %K	37%
Beta	0.56
Analysts	Strong Sell
Price Target	$44.20